Pruritus and Psoriasis - experimental analyses of itch in patients with psoriasis

Recruiting

• Conditions: L40.0; L29; Psoriasis vulgaris; Pruritus

• Registration Number: DRKS00022298
• Lead Sponsor: Klinik für Dermatologie, UKSH Campus Kiel

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with psoriasis for at least 3 months with and without pruritus. Controlgroup (no skin diseases, no itch).
- Patients with pruritus should suffer from pruritus for at least 6 weeks
- patients with a stable anti-psoriatic treatment for at least 4 weeks (with the exemption of UV-therapy and systemic corticosteroids) and/or therapy-naiv patients.
- no topical therapy for at least 3 weeks prior to testing in the location that will be evaluated
- One psoriatic lesion should be located on the back and/or thighs and/or buttocks.

Exclusion Criteria

- pregnancy or breastfeeding
- systemic corticosteroids or uv-therapy within four weeks prior to testing
- intake of NSAR, analgetics, opioids or other medikations with an influence on itch within 7 days prior to testing.
- intake of antidepressents or medication against migraine within four weeks prior to testing
- intake of gabapentin within four weeks prior to testing
- application of emolients on the day of testing
- known intolerance of capsaicin, histamin, cowhadge or other relevant substances
- other skin lesions than psoriasis (e.g. infection, tattoos) in the testlocation
- patients with a known history of atopy
- patients with a known history of polyneurophaty or other neurological diseases
- patients with a history of diabetes
- patients with a history of backpain
- diseases that in the discretion of the investigators do not allow testing (e.g. psychosomatic or psychological diseases).
- skin type IV-VI (Fitzpatrik)
- patients/controlgroup unable to consent
- drug or alcohol abuse

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The testing will take place at a certain time point. It is a one-time testing.<br>Quantitativ sensoric testing: validation of peripheral functionality of Ab, Ad and C-fibers, as well as variation of central sensibilisation.<br>endogenous pain-inhibition (CPM): central pain-inhibition will be measured using established CPM paradigm<br>Stimulation with Cowhage, histamine and Natriumchlorid.

Secondary Outcome Measures

Name	Time	Method
disease specific severity measures (e.g.: PASI, BSA)